Burden of chronic respiratory disease in Asia, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023
The Lancet Respiratory Medicine · مجلد 14 (3) · 233-255
Research outputs
مقالات ومراجعات وأوراق مؤتمرات وفصول كتب، مفهرسة برقم DOI ومربوطة بباحثي الجامعة.
723 مُخرَج نتائج البحث عن «Disease»
The Lancet Respiratory Medicine · مجلد 14 (3) · 233-255
Scientific Reports · مجلد 16 (1)
Long-term, flexible therapy strategies are needed for chronic diseases like cardiovascular ailments, diabetes, and chronic kidney disease and they have to deal with patient heterogeneity, changing physiological states and privacy constraints. This research suggests a framework for privacy-preserving and personalized artificial intelligence that combines Federated Learning (FL), a Res-HyperTransformerNet deep prediction model, Personalized Multi-Agent Reinforcement Learning (PMARL) and Explainable Artificial Intelligence (XAI) for adaptive chronic disease management. The framework is structured with two main aims: (i) to create an accurate and privacy-aware predictive model for chronic disease risk using diverse data sources, and (ii) to permit adaptive, individual therapy optimization through multi-agent reinforcement learning. Federated learning is utilized to conduct the training of Res-HyperTransformerNet over distributed Internet of Medical Things (IoMT) nodes without the requirement of transferring raw patient data. The embeddings that are created from patient data are then passed on to a PMARL module, where several agents optimize therapy dimensions like medications, diet, physical activity, and mental health interventions independently. To make the clinical support more understandable, the SHAP-based explainability method is used for both predictive and decision-making parts. The framework is tested using two public datasets—the CDC Chronic Disease dataset and the UCI Chronic Kidney Disease Risk Factor dataset. The performance is measured by employing classification metrics (accuracy, precision, recall, F1-score, MCC) as well as reinforcement learning metrics (reward score, convergence steps, episode return) and federated system metrics (communication overhead, convergence rounds, and training time). The experiments indicate that the proposed framework demonstrated improved performance in terms of predictive accuracy and policy convergence speed compared to the baseline deep learning and reinforcement learning models, and at the same time it is more cost-effective when it comes to communication in a federated setting. This means that the proposed method suggests the potential of being a reproducible and open AI framework for adaptive chronic disease therapy management. The combination of ResNet and Transformer blocks, i.e., Federated Res-HyperTransformerNet, achieved strong performance in both datasets, namely CDC Chronic Disease (Dataset 1) and UCI CKD Risk Factor (Dataset 2). The obtained accuracy for Dataset 1 was 98.61% and for Dataset 2, it was 97.75%, under the conducted experimental settings.
Scientific Reports · مجلد 16 (1)
Neurodegenerative disorders such as Parkinson’s disease are closely associated with dysregulated activity of monoamine oxidase-B (MAO-B), which leads to dopamine depletion and oxidative stress. Despite the availability of numerous monoamine oxidase (MAO) inhibitors on the market, their irreversibility and associated side effects necessitate the development of more effective and reversible MAO-B inhibitors. In this study, a series of twenty-one indole-based derivatives (PSH1 - PSH21) , collectively designated as PSH , was synthesised and evaluated for inhibitory activity against MAO isoforms. Most synthesised compounds showed higher inhibitory activity toward MAO-B than MAO-A, indicating selectivity for MAO-B. Among the PSH derivatives, PSH18 exhibited the most potent MAO-B inhibitory activity (IC 50 = 0.95 ± 0.02 µM), followed by PSH6 ( IC 50 = 1.79 ± 0.40 µM) and PSH2 (IC 50 = 1.96 ± 0.08 µM). Compound PSH18 showed the highest selectivity index value of 42.11, followed by PSH6 (22.35) and PSH2 (20.41). Additionally, PSH18 was confirmed to be a competitive and reversible inhibitor of MAO-B with an inhibition constant value of 0.89 ± 0.035 µM. Notably, PSH18 exhibited good permeability across the blood–brain barrier in parallel artificial membrane permeability assay experiments, along with acceptable absorption, distribution, metabolism, excretion, and toxicity parameters predicted through in silico modelling, suggesting its potential as a central nervous system-targeted molecule. Molecular docking and a 200 ns molecular dynamics simulation demonstrated stable binding of the ligand to the MAO-B active-site pocket, driven by hydrophobic and π–π stacking interactions with key amino acid residues lining the aromatic cage. Moreover, the calculated binding energy indicated strong ligand–protein interactions. Overall, these results indicate that the PSH scaffold could serve as a promising lead structure for the development of potent and selective MAO-B inhibitors. These compounds may have therapeutic potential for the treatment of neurodegenerative diseases.
International Journal of Polymeric Materials · مجلد 75 (8) · 835-858
Folate-conjugated chitosan nanoparticles represent a promising advancement in targeted drug delivery, offering enhanced specificity, biocompatibility, and controlled release profiles. Chitosan, a versatile biopolymer, provides a stable platform for nanoparticle synthesis, while folate conjugation enables selective targeting of folate receptors, which are overexpressed in various cancers and inflammatory diseases. This review explores the structural and functional properties of chitosan, mechanisms of folate receptor-mediated endocytosis, and innovative strategies for nanoparticle synthesis and functionalization. The review entails key formulation techniques, including nanoprecipitation, ionic gelation, and spray drying, alongside characterization methods essential for optimizing therapeutic efficacy. The biomedical applications of Folate-conjugated chitosan nanoparticles are highlighted in cancer therapy, gene delivery, and anti-inflammatory treatments, with an emphasis on emerging trends such as CRISPR-based targeting and dual-ligand strategies. This review critically examines the existing challenges and explores future directions, highlighting the promising role of folate-conjugated chitosan nanoparticles in the evolution of precision medicine.
Pathology - Research and Practice · مجلد 282 · 156440-156440
European Journal of Clinical Microbiology & Infectious Diseases · مجلد 45 (5) · 1307-1321
Frontiers in Global Women s Health · مجلد 6 · 1707792-1707792
Background: Physical activity offers numerous health benefits and helps prevent various diseases, making it an essential component of a healthy lifestyle. Objective: This study aims to examine the barriers and enablers that affect female participation in physical activity. Methods: This was a cross-sectional quantitative study. The study questionnaire was adopted from a previous study. The survey was conducted online and completed by 668 Saudi women from across the country. Results: The study findings regarding low physical activity levels among Saudi women are concerning, as 72.2% of participants were classified as sedentary or physically inactive. The study revealed that age, employment status, and income were significant factors affecting engagement of women in physical activity. Moreover, barriers such as expensive gym memberships, a lack of women-only clubs, a lack of enjoyment in sports, and prolonged use of the same exercise devices prevented Saudi women from participating in physical activities. However, women reported exercising to boost their self-satisfaction and self-confidence, thereby promoting overall health. Conclusion: Saudi women exhibit a low level of physical activity. Barriers such as expensive gym memberships, a lack of women-only clubs, a lack of enjoyment in sports, prolonged use of the same exercise devices, and motivations related to self-satisfaction and self-confidence prevent Saudi women from practicing physical activities. Health system policymakers need to take action to increase physical activity levels and address these barriers.
Nature Medicine
The Lancet Child & Adolescent Health · مجلد 10 (10) · 731-754
BACKGROUND: The Asia Pacific region is home to more than half of the world's 1·93 billion adolescents (aged 10-24 years). Addressing adolescent health in this region is of global importance, but to date a systematic analysis of key contributors to disease in adolescents has not been done, which is a barrier to responsive action. This systematic analysis of the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2023 aims to provide a comprehensive assessment of adolescent health across the Asia Pacific region, at both the subregional and national levels, encompassing burden of disease, mortality, and prevalence of adolescent risk factors. METHODS: As part of GBD 2023, we obtained estimates for cause-specific mortality, disability-adjusted life-years (DALYs), and risk factor prevalence by sex for adolescents aged 10-24 years and 5-year age groups (10-14 years, 15-19 years, and 20-24 years) across 44 countries and territories (hereafter referred to collectively as Asia Pacific), grouped by seven UN subregions, from 2000 to 2023. We extracted GBD 2023 population counts and estimates of number and rate (per 100 000 population) for mortality and disease burden (DALYs). Risk prevalence estimates were obtained directly from the Institute for Health Metrics and Evaluation, and binge drinking estimates were sourced from WHO. Estimates are reported with 95% uncertainty intervals (UIs) where possible. UIs were estimated by running 250 draws of the posterior distribution, ordering the draws, and selecting the 2·5th and 97·5th percentiles for each metric. FINDINGS: In 2023, in adolescents across Asia Pacific, there were 637 496 deaths and a total disease burden of 115·8 million DALYs, representing 34·1% of global adolescent deaths and 40·6% of the global adolescent burden of disease. Non-communicable diseases (NCDs; particularly mental disorders) were the leading causes of disease burden and mortality (64·8% of DALYs and 43·9% of deaths). Unintentional and transport injuries were also leading causes of death (14·7% of deaths due to transport injury and 13·3% of deaths due to unintentional injury) and leading causes of disease burden particularly among males in south-eastern Asia. In Melanesia, Micronesia, and some parts of south-eastern Asia (Cambodia, Indonesia, Laos, the Philippines, and Timor-Leste), respiratory infections and tuberculosis remained important contributors. Southern Asia had the largest reduction (1·5% per year) in all-cause DALYs over the study period, and Australia and New Zealand (0·2% per year) had the smallest, with females in Australia and New Zealand showing a slight increase contrary to regional trends. Eastern Asia had the largest reduction (2·8% per year) in all-cause mortality rate and Melanesia (0·8% per year) the smallest. Risk factors generally had between-subregion and within-subregion variation; however, some regional trends stood out, with overweight and obesity increasing in all countries across the region, and binge drinking increasing in more countries than not. In 2023, prevalence of smoking in males exceeded that in females in every country, from 40% difference in Timor-Leste to less than 1% difference in Australia. Anaemia prevalence is decreasing in all countries, but female prevalence was higher and reducing at a slower rate than in males. Bullying prevalence was slightly higher in Polynesia, Micronesia, and Melanesia combined, Australia and New Zealand, and eastern Asia compared with southern and south-eastern Asian subregions. INTERPRETATION: Several patterns were consistent across the region: the dominance of mental disorders and NCDs, the universal rise in overweight and obesity (particularly high in Oceanic countries but increasing rapidly in south and south-eastern Asia), and persistent sex-specific challenges across subregions: unintentional injuries and smoking in males, and anaemia in females. Actions to tackle shared risk factors (while accounting for context-specific local health profiles, workforce deficits, cultural factors, and health system capacity) should not be forgone due to local variation. Future research could focus on subnational variation, intersecting inequalities, and multi-sectoral interventions targeting shared risk factors. Priority actions should include regional investment in adolescent mental health services and obesity prevention, targeted injury reduction strategies for high-risk populations, and sex-specific approaches to smoking cessation and anaemia reduction, delivered through local health systems with the capacity and cultural responsiveness to meet local needs. FUNDING: Gates Foundation and Australian Government.
Archiv der Pharmazie · مجلد 359 (6) · e70272-e70272
Small-molecule-based therapeutics play a vital role in drug discovery. These molecules are preferred owing to their oral bioavailability, ease of tuning the physicochemical properties, and broad target accessibility. In this review article, we have explored the small molecules approved by the US Food and Drug Administration (USFDA) in 2025. Through the analysis, we found 44 drug approvals, out of which 30 candidates were approved as new molecular entities (NMEs), while the remaining 14 were approved in the category of biologics, including 10 approved as biosimilars. Considering the therapeutic area distribution of 30 NMEs, 28 drugs are approved as monotherapy, with 10 drugs as anticancer agents, 4 drugs for genetic disorders, 2 drugs each for the conditions of immunological, respiratory, ophthalmic, and endocrine disorders, along with the treatment of cardiac and infectious diseases. The structural diversity analysis revealed that 29 approved drugs were aromatic (azaheterocycles) in nature, and 13 drugs possess at least one stereogenic center. Considering the elemental diversity, the near-universal presence of nitrogen in the form of amines, amides, and as a heteroatom, followed by the oxygen atom. Additionally, the prevalence of 3- or 4-membered carbocyclic or heterocyclic rings was found in five approved drugs. For metabolism, most drugs rely on CYP3A-mediated metabolism, primarily through CYP3A4, CYP2D6, and CYP2C8. Collectively, the analysis and compilation of the drugs presented are expected to provide practical insights and offer guidance to medicinal chemists, biologists, and scientists associated with current drug-discovery paradigms, making continuous strides for future medicinal chemistry innovations and evolutions.
Cureus · مجلد 18 (2) · e103029-e103029
Type 2 diabetes mellitus (T2DM) increases the risk of cardiovascular morbidity and end-stage renal disease. Renin-angiotensin-aldosterone system (RAAS) inhibitors, specifically angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs), are standard therapies for organ protection. However, uncertainty remains regarding their comparative efficacy and the safety of combination therapy. This systematic review and meta-analysis aimed to compare the efficacy of ACEIs versus ARBs in reducing cardiovascular and renal events in patients with T2DM and to assess the safety of dual blockade. PubMed, EMBASE, and Cochrane databases were searched for randomized controlled trials (RCTs) published up to 2025 comparing ACEIs, ARBs, or their combination against placebo or active controls in T2DM patients. The primary outcome was a composite of cardiovascular death, myocardial infarction, stroke, and renal failure. Methodological quality was assessed using the Cochrane Risk of Bias 2 tool. Data were synthesized using frequentist pairwise and Bayesian network meta-analyses. Heterogeneity was explored via meta-regression, and trial sequential analysis (TSA) was used to assess the sufficiency of evidence. In total, 16 RCTs involving 47,406 participants were included. In pairwise analysis, both ACEIs (risk ratio (RR) = 0.87, 95% confidence interval (CI) = 0.81-0.94) and ARBs (RR = 0.90, 95% CI = 0.83-0.98) significantly reduced the risk of the primary composite endpoint compared to control. Network meta-analysis showed no statistically significant difference between ACEIs and ARBs (RR = 0.98, 95% CI = 0.88-1.09). Although ACEIs ranked slightly higher in probability for reducing all-cause mortality (surface under the cumulative ranking = 78% vs. 65%), this difference was not statistically significant. Dual blockade (ACEI + ARB) increased the risk of hyperkalemia (RR = 2.8) and acute kidney injury (RR = 1.7) without improving efficacy. Meta-regression identified baseline systolic blood pressure as a significant modifier of treatment benefit (p = 0.04). TSA indicated that the evidence for the RAAS blockade's benefit is conclusive. ACEIs and ARBs exhibit comparable efficacy in preventing cardiovascular and renal events in patients with T2DM, with a marginal mortality benefit favoring ACEIs. Dual blockade is associated with increased harm and is not recommended. Monotherapy with either agent remains the preferred strategy for organ protection.
ChemistrySelect · مجلد 11 (2)
ABSTRACT This research explores the capacity of phenyl styryl ketone derivatives to inhibit monoamine oxidase B (MAO‐B), a key enzyme associated with neurodegenerative disorders. From frontier molecular orbital (FMO) studies, reactivity parameters of the drug candidates were found out. Ligands were submitted to absorption, digestion, metabolism, excretion, and toxicity (ADMET) analysis to ensure their potential drugability and safety. To understand the electronic description of ligand interaction, natural bond orbital (NBO) analysis was conducted, and the presence of heteroatoms was proven crucial. The reduced density gradient (RDG) studies, together with molecular electrostatic surface potential (MESP) analysis, were able to provide the ligand's active sites and nature of interaction. Docking studies were conducted to study the interaction between the protein (P) and ligand (L) at the MAO‐B catalytic region, alongside a comparison with safinamide, a recognized MAO‐B inhibitor. Molecular dynamics (MD) simulations were utilized to examine the protein–ligand complex (PLC). The molecular mechanics Poisson–Boltzmann surface area (MM‐PBSA) method was applied to predict the binding affinity and interaction. We also analyzed structural stability, solvation, and decomposition. Of the four ligands examined, CHA_1.4 is found to be the most efficient. The contact map method was useful in identifying the key amino acids; in all the complexations we have considered, TYR398 has interacted most with the drug candidates. The finding was in agreement with the decomposition profile of the PLC. For the principal component analysis (PCA), topology formats and 100 ns MD trajectories are used to learn more about how proteins fold. Replicates were also done to validate the reported study and are represented as box‐whisker plots. The study's findings provide valuable insights for the development of new MAO‐B inhibitors.
Frontiers in Aging Neuroscience · مجلد 18
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), originally developed as antidiabetic agents, have emerged as candidate disease-modifying therapies for Parkinson’s disease (PD) and Alzheimer’s disease (AD), reflecting the widespread expression of GLP-1 receptors across neurons, glia, and the cerebral vasculature. This narrative review synthesizes mechanistic, clinical trial, and biomarker evidence for GLP-1 RAs in PD and AD, based on a literature search of PubMed, Embase, Scopus, and Web of Science, with ClinicalTrials.gov searched separately for trial protocols and results, through May 2026. Preclinical data implicate GLP-1 receptor agonism in anti-neuroinflammatory signaling, mitochondrial preservation, autophagy and proteostasis enhancement, anti-apoptotic effects, synaptic plasticity, cerebrovascular protection, and glymphatic clearance. Clinical evidence in PD is mixed and agent- and formulation-dependent: the phase II Exenatide-PD trial reported a motor benefit that persisted after washout (∼3.5-point between-group difference in MDS-UPDRS Part III), and the phase II LIXIPARK trial (lixisenatide) reported a significant 3.08-point between-group difference (95% CI 0.86–5.30; p = 0.007) favoring lixisenatide, whereas the larger, longer phase III Exenatide-PD3 trial, using an extended-release weekly formulation, found no significant effect on the same endpoint (adjusted coefficient 0.92; 95% CI −1.56 to 3.39; p = 0.47); oral semaglutide is under investigation in the ongoing phase II MOST-ABLE trial. In AD, the phase IIb liraglutide (ELAD) trial did not achieve statistical benefit on either its primary imaging endpoint (cerebral glucose metabolic rate; p = 0.14) or on most secondary cognitive measures, and the phase III semaglutide trials EVOKE and EVOKE+ did not meet their primary CDR-SB endpoint (estimated difference −0.08, 95% CI −0.35 to 0.20, p = 0.57 in EVOKE; 0.10, 95% CI −0.17 to 0.38, p = 0.46 in EVOKE+), despite biomarker signals including reductions in cerebrospinal fluid tau species and inflammatory markers. Comparative pharmacology reveals substantial heterogeneity in central nervous system penetration, receptor engagement, and systemic bioavailability across exenatide, liraglutide, semaglutide, and the imbalanced GLP-1/GIP co-agonist tirzepatide, complicating cross-agent extrapolation. Persistent challenges include separating direct neuroprotection from indirect metabolic and cardiovascular benefit, limited characterization of brain drug exposure, trial durations that may be short relative to the expected latency of a disease-modifying effect, and the absence of validated response biomarkers. We conclude that although the mechanistic and epidemiological rationale for GLP-1 RAs in neurodegeneration remains biologically plausible, current trial evidence does not yet support their use outside clinical trials, irrespective of comorbid diabetes status; future studies should prioritize earlier intervention, biomarker-guided patient selection, adequately powered subgroup analyses, and brain-penetrant formulations.
The Lancet Public Health
BACKGROUND: Unintentional poisoning is a preventable cause of injury-related morbidity and mortality, yet global patterns, trends, and inequalities remain incompletely characterised. Within the Global Burden of Disease (GBD) framework, unintentional poisoning includes poisoning by carbon monoxide and poisoning by other means, a category largely informed by pesticide poisoning codes plus some indirect capture of other poisoning as part of the GBD re-distribution process. Poisonings by pharmaceuticals and illicit substances are not captured in the GBD definition of poisoning. We aimed to quantify this GBD-defined burden and assess regional variation, sociodemographic gradients, and case fatality between 1990 and 2023. METHODS: We analysed GBD 2023 estimates for 204 countries and territories, modelling deaths, incidence, and disability-adjusted life-years (DALYs) using standard GBD cause-of-death and non-fatal estimation methods with 95% uncertainty intervals. We stratified results by age, sex, region, and Socio-demographic Index (SDI), and derived case fatality from modelled deaths and incidence. FINDINGS: In 2023, unintentional poisoning from carbon monoxide and other means caused 2·54 million incident poisonings, 69 805 deaths, and 3·68 million DALYs globally, with age-standardised DALY rates declining by 47·5% since 1990. Carbon monoxide accounted for 641 932 poisonings, 30 890 deaths and 1·34 million DALYs, with the highest burdens in central and eastern Europe and central Asia. Most regions showed substantial long-term declines, and the global age-standardised DALY rate for carbon monoxide poisoning declined by 58·2% since 1990. Poisoning by other means caused 1·90 million incident cases, 38 914 deaths, and 2·34 million DALYs, with the greatest burden in sub-Saharan Africa. Most regions showed declining age-standardised DALY rates for poisoning by other means; however, there was no clear change (with the 95% uncertainty interval including zero) in the global estimate, driven by wide uncertainty intervals in several regions (including sub-Saharan Africa). Mortality and DALYs were inversely associated with SDI, and derived case fatality was highest in low-SDI regions. INTERPRETATION: Global reductions in GBD-defined unintentional poisoning by carbon monoxide and other means are consistent with decades of regulatory and environmental interventions. These include bans of highly toxic pesticides, improved heating and ventilation systems, emissions controls, and adoption of carbon monoxide alarms. Stark inequalities persist in some regions and in low-SDI settings. Compared with previous GBD publications, this study provides a detailed global assessment of unintentional poisoning by carbon monoxide and other means up to 2023, integrating incidence, DALYs, and comparative case fatality across regions. FUNDING: Gates Foundation and the Australian National Health and Medical Research Council.
Current Bioactive Compounds · مجلد 22
Introduction: Neurodegenerative diseases present major challenges in biomedical research, and identifying natural sources with potential cytoprotective effects remains an important exploratory goal. This study investigates the cytoprotective properties of Fagonia arabica in human neuroblastoma (SK‑N‑SH) cells exposed to oxidative and neurotoxic stressors. Methods: he dried plant material was subjected to a sequential solvent extraction method. The antioxidant and anti-inflammatory activity was assessed by standard procedures. Cytotoxicity was assessed in L929 fibroblasts, and in vitro neuroprotective effects were examined in SK‑N‑SH neuroblastoma cells exposed to trimethyltin (TMT). The GCMS analysis identified the phytocompounds, and an in silico study was performed using molecular docking against targeted proteins. Results: The phytochemical analysis identified phytochemicals like flavonoids, alkaloids, and phenols. In silico analysis indicated that several detected phytochemicals showed notable binding affinity toward targets associated with oxidative stress and inflammation. The extract exhibited anti-inflammatory effects in protein denaturation (IC50 141.88 µg/mL) and COX-2 inhibition assays (IC50 53.65 µg/mL), along with antioxidant activity via DPPH scavenging (IC50 138.14 µg/mL). Cytotoxicity testing demonstrated low toxicity in L929 cells (IC50 = 162.43 µg/mL). In the TMT‑injury model, the extract improved SK‑N‑SH cell viability (86.52% at 50 µg/mL), indicating potential cytoprotective activity under oxidative stress conditions. Results: The phytochemical analysis identified phytochemicals like flavonoids, alkaloids, and phenols. In silico analysis indicated that several detected phytochemicals showed notable binding affinity toward targets associated with oxidative stress and inflammation. The extract exhibited anti-inflammatory effects in protein denaturation (IC50 141.88 µg/mL) and COX-2 inhibition assays (IC50 53.65 µg/mL), along with antioxidant activity via DPPH scavenging (IC50 138.14 µg/mL). Cytotoxicity testing demonstrated low toxicity in L929 cells (IC50 = 162.43 µg/mL). In the TMT‑injury model, the extract improved SK‑N‑SH cell viability (86.52% at 50 µg/mL), indicating potential cytoprotective activity under oxidative stress conditions. Discussion: The biological activities of the extract are likely due to its phytochemical constituents, particularly flavonoids and phenolic compounds. The in silico predictions supported the experimental findings of anti-inflammatory and antioxidant activities. The extract also showed low cytotoxicity and demonstrated cytoprotective effects under oxidative stress conditions, suggesting potential therapeutic value, warranting further investigation into its mechanisms and pharmacological applications. Conclusion: Fagonia arabica demonstrated antioxidant, anti-inflammatory, and preliminary neuroprotective effects at the cellular level. While these findings support the plant’s potential as a source of bioactive compounds with neuroprotective potential, the study does not directly model the complex pathology of Alzheimer’s disease. Further investigations using disease-relevant models are required to clarify its therapeutic relevance